Abstract
Methods The study was performed in 25 JIA patients who donated paired serum samples prior and one year after continous etanercept therapy. Basic clinical data (six core set variables defined in ACR PEDI outcome score) were recorded along with alkalyne DnaseI serum levels using the method where acid soluble nucleotides are determined spectrophotometrically at 260 nm. Treatment schedule of etanercept was 0, 4 mg/kg body weight subcutaneously twice weekly.
Highlights
Failure to efficiently degrade the DNA of apoptotic cells activates innate immunity causing chronic arthritis
15th Paediatric Rheumatology European Society (PreS) Congress Wietse Kuis, Patricia Woo, Angelo Ravelli, Hermann Girschick, Michaël Hofer, Johannes Roth, Rotraud K Saurenmann, Alberto Martini, Pavla Dolezova, Janjaap van der Net, Pierre Quartier, Lucy Wedderburn and Jan Scott Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here.
Our results indicate significant increase of DNaseI in the sera of JIA patients after one year of anti TNFα therapy which was associated to the disease clinical improvement
Summary
Address: 1Ped Rheumatol, Faculty of Medicine, Nis, Serbia and 2Institute of Rheumatology, Belgrade, Serbia * Corresponding author from 15th Paediatric Rheumatology European Society (PreS) Congress London, UK. 14–17 September 2008. Address: 1Ped Rheumatol, Faculty of Medicine, Nis, Serbia and 2Institute of Rheumatology, Belgrade, Serbia * Corresponding author from 15th Paediatric Rheumatology European Society (PreS) Congress London, UK. Published: 15 September 2008 Pediatric Rheumatology 2008, 6(Suppl 1):P38 doi:10.1186/1546-0096-6-S1-P38. 15th Paediatric Rheumatology European Society (PreS) Congress Wietse Kuis, Patricia Woo, Angelo Ravelli, Hermann Girschick, Michaël Hofer, Johannes Roth, Rotraud K Saurenmann, Alberto Martini, Pavla Dolezova, Janjaap van der Net, Pierre Quartier, Lucy Wedderburn and Jan Scott Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
